29 June 2015
Genomic technology company Illumina has announced plans to build a major new science centre and European headquarters in the Cambridge life science cluster.
The firm has signed a 20-year lease for a 155,000 square foot facility, which is designed to seamlessly spread up to 70,000 square feet as needed for future expansion. The new deal adds to Illumina’s presence in Cambridge; previously the firm bought two pioneering Cambridge MedTech companies, Solexa and BlueGnome.
Illumina’s CFO Mark Stapley said: "This new state-of-the-art European Headquarters will provide enhanced collaboration opportunities for our growing employee base, which is so foundational to Illumina's innovation and success".
The new European HQ will be based in Granta Park, a science research centre not far from Cambridge that is owned, managed and operated by BioMed Realty Trust. In three years BioMed Realty has developed 700,000 square feet of lab and office space to satisfy Cambridge’s thriving life science sector.
Undersecretary of state for life sciences, George Freeman said: "Illumina and BioMed Realty's commitment to building a new state-of-the art facility in Cambridge is great news for our area…This is a strong endorsement of the UK's Life Science Industrial Strategy and leadership in driving forward better treatments for people with cancers and rare diseases".
The announcement follows on from news that pharma giant AstraZeneca’s plans to create a £330 million global HQ in Cambridge has received approval from the city council. Cambridge is rapidly consolidating existing strengths to become a leading global hub for biomedical research and development.